Amgen K-Ras Targeted Lung Cancer Drug

Last week we were talking about Luma-Kris, which is the Amgen K-RAS targeting lung cancer drug. They did show a small benefit on tumor progression of about 1.1 months over a standard chemotherapy. But maybe just as importantly, you know, they looked at survival in the study and there was no difference from a statistical standpoint. And so it's a little bit of a setback for this drug, which had kind of been, kind of had a lot of optimism and hype around it.